GxP & Quality Management Systems
GxP is the umbrella term for the "good practice" regulatory frameworks that govern regulated research and manufacturing: Good Laboratory Practice (GLP, non-clinical safety studies), Good Clinical Practice (GCP, human trials, codified internationally in ICH E6), and Good Manufacturing Practice (GMP, production). This sub-cluster covers what each framework actually requires, how a research-setting quality management system (QMS) is typically structured around them — standard operating procedures (SOPs), deviation handling, corrective and preventive action (CAPA), and change control — and how these requirements differ from the general-purpose ISO 9001 QMS standard, which governs commercial quality systems rather than regulated research specifically.
Guides
E2B(R3) Data Elements: A Practical ICSR Submission Reference
A practical, section-by-section reference to E2B(R3) ICSR data elements: mandatory vs conditional vs optional, null flavours, and how ICH regional implementation guides layer on top of the core standard.
ICH E6(R3) Annex 2: Remote Monitoring, Telehealth Visits, and Direct-to-Patient Shipment Oversight
A deep dive into ICH E6(R3) Annex 2’s decentralised-trial provisions: remote and risk-based monitoring, telehealth-based visits, and sponsor oversight of direct-to-patient investigational product shipment.
Designing a GxP Compliance Training Programme
How to design a GxP training programme by role — QA, production, and lab — with the delivery method, effectiveness verification, and training-record retention an inspector actually checks.
Running a Mock FDA Inspection: Roles, Document Requests, and Trip-Wire Questions
A practical guide to running a mock FDA inspection: front-room and back-room roles, simulating the document-request cycle, common trip-wire interview questions, and closing findings through CAPA.
Annual Product Quality Review (APQR): Required Data Inputs and How to Build One
APQR’s required data-source inputs under 21 CFR 211.180(e) — batch records, OOS results and deviations, stability data, complaints/recalls/returns, and change control — plus how the U.S. Annual Product Quality Review differs from the EU’s Product Quality Review (PQR) under EU GMP Chapter 1.10, and how to write the trending and conclusions sections an inspector expects.
eCTD Module 3 Quality: A Section-by-Section Map of 3.2.S and 3.2.P
A section-by-section map of eCTD Module 3 quality: every 3.2.S drug-substance and 3.2.P drug-product subsection, what belongs in 3.2.A and 3.2.R, and the granularity reviewers expect.
Deviation Management in a Regulated Lab: Classification, Investigation Depth, and Planned vs. Unplanned
Deviation management is its own quality-system process, not a CAPA subroutine: how planned and unplanned deviations get identified, classified as minor/major/critical, and investigated at a depth that scales to that classification.
Reference Safety Information (RSI): What It Is and What Changes When It’s Updated
Reference safety information (RSI) is the version-controlled subset of the Investigator’s Brochure — or a comparator’s approved labeling — used to decide whether an adverse event is expected. Here’s where it lives, how it’s kept current, and what actually changes when it’s updated mid-trial.
OOS Investigation: The FDA Two-Phase Process
How the FDA two-phase OOS investigation works: the Phase I laboratory investigation and hypothesis testing that can invalidate a result, the Phase II full-scale production investigation when it can’t, and the retesting/resampling rules that trace back to Barr Laboratories v. United States.
ICH E6(R3) Data Governance Requirements
How ICH E6(R3)’s Principles govern clinical trial data: the data lifecycle, quality-by-design applied to data, technology-agnostic (media-neutral) requirements, and traceability from source to reported result.
Root Cause Analysis for CAPA: Choosing 5 Whys, Fishbone, or Fault Tree
A GxP deviation investigation only prevents recurrence if it reaches a true system-level root cause instead of stopping at “operator error.” This guide covers how to choose between 5 Whys, fishbone/Ishikawa diagrams, and fault tree analysis by problem type, and the specific failure mode each technique exists to catch.
CAPA Process Steps: The Six-Stage Workflow, Roles, and Approval Gates
The CAPA process as a sequence of six stages — identify, investigate, plan, implement, verify effectiveness, close — with who owns each step, the handoff to the next, and the approval gate that has to clear first.
Signal Detection in Pharmacovigilance: A Practical Process Guide
A practical process guide to pharmacovigilance signal detection: disproportionality analysis (PRR, ROR, EBGM) with a worked PRR/ROR calculation from a 2×2 table, and the validation-to-recommendation review pipeline that turns a statistical flag into a documented safety decision.
Standardised MedDRA Queries (SMQs): Narrow vs. Broad Scope and When to Use Each
How SMQ narrow and broad scope differ, what algorithmic and hierarchical SMQs add, and how each is actually used in signal detection and aggregate safety review — a practical application guide, not a definitions page.
Change Control in Pharma: Classification, Impact Assessment, and Regulatory Filing Triggers
How pharma change control classifies a proposed change as like-for-like, minor, or major, what the impact assessment has to cover, and the point where a classification decision triggers a PAS/CBE/Annual Report or EU variation filing — as its own process, distinct from CAPA and document control.
MedWatch Form 3500A: Section-by-Section (vs. the Voluntary 3500)
A section-by-section walkthrough of FDA MedWatch Form 3500A, the mandatory adverse-event report: what triggers its use over the voluntary Form 3500, the fields first-time filers get wrong, and why device reports route to a different electronic system than FAERS.
FDA Prescription Drug Labeling: The 201.56/201.57 Section Map
A section-by-section map of 21 CFR 201.56/201.57: the exact required order for Highlights and Full Prescribing Information, boxed warning placement, and how to use the structure as a review checklist.
ICSR Processing Workflow: Intake to Submission
The ICSR processing workflow end to end: intake channels, triage, duplicate detection, coding, causality assessment, medical review, QC, submission, and follow-up.
Cleaning Validation: Worst-Case Grouping, MACO, and Acceptance Limits
A worked decision process for cleaning validation: worst-case product and equipment grouping, MACO calculation via dose-based, 10 ppm, and health-based (PDE/ADE) acceptance-limit methods, and choosing swab vs. rinse sampling.
21 CFR Part 58: GLP Requirements for Nonclinical Studies
How 21 CFR Part 58 governs nonclinical safety studies: the study director’s single-point authority, quality assurance unit independence, protocol and SOP amendments and deviations, and archiving requirements for GLP-compliant testing facilities.
The SOPs a Clinical Trial Site Actually Needs
Which SOPs a clinical trial site or sponsor actually needs, and what each one has to specify: informed consent, AE/SAE reporting, source documentation, and monitoring visit preparation.
Process Performance Qualification (PPQ): Protocol Design, Sampling, and Acceptance Criteria
How Process Performance Qualification (PPQ) fits into the FDA three-stage process validation lifecycle, how it differs from equipment IQ/OQ/PQ, and how to justify a PPQ protocol’s batch count, sampling plan, and acceptance-criteria statistics.
Document Control Procedure: The Six-Stage Lifecycle
How a document control procedure governs draft, review, approval, distribution, revision, and withdrawal for controlled documents in a GxP quality system — and the exact record each stage has to leave for an audit.
ICH E8(R1) General Considerations for Clinical Studies: What Changed
ICH E8(R1) replaced a general-principles checklist with quality by design: critical-to-quality factors and proportionate monitoring, identified during protocol planning — and the framework ICH E6(R3) was restructured to carry into trial conduct.
EudraVigilance Reporting: Registration, EVWEB vs Gateway, and ICSR Timelines
How EudraVigilance registration, EVWEB and gateway submission, the E2B(R3) ICSR format, and EU reporting timelines actually work for MAHs and clinical trial sponsors.
21 CFR 210 and 211: A Subpart-by-Subpart Map of cGMP Requirements
21 CFR 210 sets the legal minimum for drug cGMP; 21 CFR 211 spells it out across eleven subparts. This guide maps every subpart to its section range and what it actually requires.
Quality Management System for a Laboratory: Building It From the Process Approach Up
A laboratory QMS is a system of interacting processes, not a single document. Which accreditation/regulatory framework actually applies (ISO 17025, ISO 15189, GLP, GxP), the document hierarchy underneath it, and the records each framework adds on top of the common core.
GVP Module VI: ICSR Collection, Validation, and Reporting Timelines
How GVP Module VI defines a valid ICSR, distinguishes solicited from spontaneous reports, handles special situations like pregnancy and off-label use, and sets the 15-day/90-day EudraVigilance reporting clocks.
Quality Manual for a Regulated Organisation: Scope, Process Interactions, and ISO 13485 vs. GMP
A regulatory quality manual is an auditable artefact with defined scope, justified exclusions, process interactions, and a document-hierarchy outline — not a marketing statement of intent. Here is what ISO 13485:2016 clause 4.2.2 actually requires, and why GMP frameworks handle the same territory through a different document altogether.
Aseptic Process Simulation (Media Fill) Design Under Annex 1
How EU GMP Annex 1 (points 9.32-9.49) specifies aseptic process simulation design: number and size of runs, which interventions to simulate, incubation, acceptance criteria, and the required investigation when a single unit is contaminated.
QPPV Role and Responsibilities: Qualifications, Residency, and 24/7 Availability
What the EU QPPV role actually requires: qualifications, the EU/EEA residency rule, 24-hour availability, which duties can never be delegated, the deputy arrangement, and national contact-person requirements layered on top of the EU role.
EU GMP Annex 1: The 2022 Sterile Manufacturing Revision Explained
The 2022 EU GMP Annex 1 revision changed how sterile manufacturers document contamination control, protect first air, size Grade A zones, and validate aseptic processing.
CAPA Report and Plan Structure: The Six Sections Auditors Check
The CAPA record structure that holds up under audit: problem statement, extent-of-condition, root cause with evidence, an action plan with owners and dates, effectiveness criteria, and closure approval.
PSUR and PBRER Format: ICH E2C(R2) Section by Section
A section-by-section walkthrough of the PSUR/PBRER format under ICH E2C(R2), covering the data lock point, reporting-interval rules, the integrated benefit-risk evaluation, and the EU single assessment procedure (PSUSA).
ICH Q2(R2) Analytical Procedure Validation: Which Tests Apply, What Changed from Q2(R1), and How It Pairs with Q14
ICH Q2(R2) and ICH Q14 were adopted at Step 4 together on 1 November 2023. This guide sets out the Q2(R2) Table 1 test-selection matrix by measured quality attribute, the eight substantive changes from Q2(R1), the Table 2 reportable-range thresholds, and how validation, verification and transfer differ.
ICH E6(R3) Definitions: Audit, Inspection, Monitoring and Quality Assurance
What ICH E6(R3) actually says an audit, an inspection, monitoring and quality assurance are — each definition quoted verbatim from the Step 4 Glossary — then the distinction that matters in practice: who performs it, on whose authority, and what the output obliges. Includes a word-level cross-walk to the E6(R2) text still quoted across much of the web, and a map from R2 section numbers to their E6(R3) Annex 1 replacements.
Structured Product Labeling (SPL): Document Types, Data Elements, and the Validation Rules That Cause Rejection
A practical guide to authoring and submitting FDA Structured Product Labeling (SPL): the three registration and listing submissions, required data elements, the numbered validation procedures that cause rejection, the annual October-to-December calendar, and how SPL reaches DailyMed.
Nonconformity: ISO Definition, Major vs. Minor, and the NCR/NCAR Process
ISO 9000:2015 defines a nonconformity as the non-fulfilment of a requirement. This guide covers the definition, major-vs-minor classification, the NCR/NCAR record, and how the concept appears in ISO 9001, ISO 17025, and ISO 13485.
GxP Compliance: What GLP, GCP, GMP, and GDP Actually Require
GxP is an umbrella term for GLP, GCP, GMP, GDP, and related “Good … Practice” frameworks. This guide explains what they share, which one applies to which stage of work, and where academic research sits outside all of them.
